123 related articles for article (PubMed ID: 4067520)
1. Clinical significance of free plasma hydroxyproline measurement in metabolic bone disease.
Minisola S; Antonelli R; Mazzuoli G
J Clin Chem Clin Biochem; 1985 Sep; 23(9):515-9. PubMed ID: 4067520
[TBL] [Abstract][Full Text] [Related]
2. New biochemical marker for bone metabolism. Measurement by radioimmunoassay of bone GLA protein in the plasma of normal subjects and patients with bone disease.
Price PA; Parthemore JG; Deftos LJ
J Clin Invest; 1980 Nov; 66(5):878-83. PubMed ID: 6968755
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of urinary hydroxypyridinium crosslink measurements as resorption markers in metabolic bone diseases.
Robins SP; Black D; Paterson CR; Reid DM; Duncan A; Seibel MJ
Eur J Clin Invest; 1991 Jun; 21(3):310-5. PubMed ID: 1909635
[TBL] [Abstract][Full Text] [Related]
4. Relationship of the activity of the bone isoenzyme of serum alkaline phosphatase to urinary hydroxyproline excretion in metabolic and neoplastic bone diseases.
Stĕpán J; Pacovský V; Horn V; Silinková-Málková E; Vokrouhlická O; Konopásek B; Formánková J; Hrba J; Marek J
Eur J Clin Invest; 1978 Dec; 8(6):373-7. PubMed ID: 105909
[TBL] [Abstract][Full Text] [Related]
5. Serum total hydroxyproline assay: effects of age, sex and Paget's bone disease.
Gilbertson TJ; Brunden MN; Gruszczyk SB; Whyte MP; Burnett MA
J Clin Chem Clin Biochem; 1983 Mar; 21(3):129-32. PubMed ID: 6854222
[TBL] [Abstract][Full Text] [Related]
6. [Primary hyperparathyroidism in a patient with Paget's bone disease].
Guijarro de Armas MG; Pavón de Paz I; Zubieta Tabernero J; Civantos Modino S; Montaño Martínez JM; Díaz Guardiola P
Endocrinol Nutr; 2010 Apr; 57(4):170-3. PubMed ID: 20381437
[No Abstract] [Full Text] [Related]
7. Osteocalcin and bone remodelling in Paget's disease of bone, primary hyperparathyroidism, hypercalcaemia of malignancy and involutional osteoporosis.
Torres R; de la Piedra C; Rapado A
Scand J Clin Lab Invest; 1989 May; 49(3):279-85. PubMed ID: 2787049
[TBL] [Abstract][Full Text] [Related]
8. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease.
Alvarez L; Guañabens N; Peris P; Monegal A; Bedini JL; Deulofeu R; Martinez de Osaba MJ; Muñoz-Gomez J; Rivera-Fillat F; Ballesta AM
J Bone Miner Res; 1995 Mar; 10(3):458-65. PubMed ID: 7785468
[TBL] [Abstract][Full Text] [Related]
9. [Effect of secondary hyperparathyroidism upon serum hydroxyproline in patients with renal failure].
Mysiak W; Stasiak L
Pol Arch Med Wewn; 1991 May; 85(5):278-85. PubMed ID: 1896393
[TBL] [Abstract][Full Text] [Related]
10. Changes in plasma bone GLA protein during treatment of bone disease.
Deftos LJ; Parthemore JG; Price PA
Calcif Tissue Int; 1982 Mar; 34(2):121-4. PubMed ID: 6805917
[TBL] [Abstract][Full Text] [Related]
11. [Deoxypyridinoline and other biochemical markers of bone resorption in distinct pathologies].
Rivero Marcotegui A; Palacios Sarrasqueta M; Grijalba Uche A; Martínez Rodríguez JL; Sorbet Zubiría MJ; García Merlo S
Rev Clin Esp; 1997 Jun; 197(6):389-92. PubMed ID: 9304127
[TBL] [Abstract][Full Text] [Related]
12. The effect of nasal hCT on bone turnover in Paget's disease of bone--implications for the treatment of other metabolic bone diseases.
Reginster JY; Jeugmans-Huynen AM; Wouters M; Sarlet N; McIntyre HD; Franchimont P
Br J Rheumatol; 1992 Jan; 31(1):35-9. PubMed ID: 1730104
[TBL] [Abstract][Full Text] [Related]
13. Low serum magnesium concentration in Paget's disease of bone (osteitis deformans).
Taylor WH
Ann Clin Biochem; 1985 Nov; 22 ( Pt 6)():591-5. PubMed ID: 4073791
[TBL] [Abstract][Full Text] [Related]
14. Clinical usefulness of serum tartrate-resistant acid phosphatase activity determination to evaluate bone turnover.
Scarnecchia L; Minisola S; Pacitti MT; Carnevale V; Romagnoli E; Rosso R; Mazzuoli GF
Scand J Clin Lab Invest; 1991 Oct; 51(6):517-24. PubMed ID: 1767245
[TBL] [Abstract][Full Text] [Related]
15. Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone disease.
Seibel MJ; Woitge HW; Pecherstorfer M; Karmatschek M; Horn E; Ludwig H; Armbruster FP; Ziegler R
J Clin Endocrinol Metab; 1996 Sep; 81(9):3289-94. PubMed ID: 8784085
[TBL] [Abstract][Full Text] [Related]
16. [A test for acute hypocalcemia using swine and salmon calcitonin].
Fournié A; Valverde C; Tap G; Bazerque JJ; Ayrolles C
Rev Rhum Mal Osteoartic; 1977 Feb; 44(2):91-8. PubMed ID: 847364
[TBL] [Abstract][Full Text] [Related]
17. The measurement of urinary amino-terminal telopeptides of type I collagen to monitor bone resorption in patients with primary hyperparathyroidism.
Minisola S; Pacitti MT; Rosso R; Pellegrino C; Ombricolo E; Pisani D; Romagnoli E; Damiani C; Aliberti G; Scarda A; Mazzuoli SF
J Endocrinol Invest; 1997 Oct; 20(9):559-65. PubMed ID: 9413811
[TBL] [Abstract][Full Text] [Related]
18. [Short-term biological effects of synthetic salmon calcitonin in Paget's disease. Influence of posology].
Chapuy MC; Meunier P; Terrier M; David L; Vignon G
Pathol Biol (Paris); 1975 May; 23(5):349-59. PubMed ID: 172838
[TBL] [Abstract][Full Text] [Related]
19. Parathyroid function in Paget's disease of bone.
Siris ES; Clemens TP; McMahon D; Gordon A; Jacobs TP; Canfield RE
J Bone Miner Res; 1989 Feb; 4(1):75-9. PubMed ID: 2718781
[TBL] [Abstract][Full Text] [Related]
20. Prediction of the outcome of treatment of Paget's disease of bone with bisphosphonates from short-term changes in the rate of bone resorption.
Papapoulos SE; Frölich M
J Clin Endocrinol Metab; 1996 Nov; 81(11):3993-7. PubMed ID: 8923849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
